Smith Christopher Daniel, De Luca Adrian, Hibbert Peter, Sundararajan Krishnaswamy
Intensive Care Unit, Royal Adelaide Hospital, Adelaide, South Australia, Australia
School of Medicine, The University of Adelaide, Adelaide, South Australia, Australia.
BMJ Open Qual. 2025 Jan 8;14(1):e002911. doi: 10.1136/bmjoq-2024-002911.
Transfusion of blood products following cardiothoracic surgery represents a significant proportion of national blood product usage, has significant cost implications and is associated with increased 30-day mortality. Following identification of an increase in blood product use, we implemented a healthcare improvement initiative using a perioperative care model and establishment of a new multispecialty cardiothoracic surgery taskforce to further define and tackle the problem. The initiative incorporated a bundle of preoperative identification of high-risk patients, an intraoperative haemostasis checklist, a programme of unit education focussing on bleeding postbypass and use of thromboelastography and introduction of postoperative protocols for identification and escalation of bleeding. Following intervention, a 60% reduction in blood product use within the first 12 hours of cardiopulmonary bypass was observed. Red cell, cryoprecipitate and fresh frozen plasma usage were particularly reduced with 57%, 47% and 72% reductions, respectively, following intervention and similar results were maintained on repeat audit 1-year postintervention, with on average 84 fewer blood products used per 100 patients. This resulted in an estimated cost saving of AU$36 928 per 100 patients. This quality initiative was successful in overcoming traditional silos of care and describes how quality improvement methodology utilising a multispecialty and multidisciplinary approach can be applied to solve complex issues in the perioperative period. Here, we demonstrate a reproducible and sustainable model for reducing blood product use in the cardiothoracic perioperative population.
心胸外科手术后的血液制品输注占全国血液制品使用量的很大比例,具有重大的成本影响,且与30天死亡率增加相关。在发现血液制品使用量增加后,我们实施了一项医疗改进计划,采用围手术期护理模式并成立了一个新的多专科心胸外科特别工作组,以进一步明确和解决该问题。该计划包括一系列措施:术前识别高危患者、术中止血检查表、针对体外循环后出血及血栓弹力图使用的科室教育计划,以及引入术后出血识别和上报方案。干预后,观察到体外循环后12小时内血液制品使用量减少了60%。红细胞、冷沉淀和新鲜冰冻血浆的使用量尤其减少,干预后分别减少了57%、47%和72%,干预后1年的重复审核维持了类似结果,每100例患者平均少用84个血液制品。这估计每100例患者节省成本36928澳元。这项质量改进计划成功克服了传统的护理壁垒,并描述了如何运用多专科和多学科方法的质量改进方法来解决围手术期的复杂问题。在此,我们展示了一种可重复且可持续的模式,用于减少心胸外科围手术期患者的血液制品使用量。